Education
About Us
Working with TipRanks
Follow Us
10x Genomics Inc (TXG)
NASDAQ:TXG
TXG Analyst Ratings
Moderate Buy
3 Buy
8 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
TXG Stock 12 Month Forecast
Average Price Target
$17.89
▼(-7.26% Downside)
| Highest Price Target$22.00 | Average Price Target$17.89 | Lowest Price Target$14.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Canaccord Genuity
$20
Buy
3.68%
Upside
Reiterated
01/12/26
William Blair
Hold
―
Assigned
01/12/26
TD Cowen
$18
Hold
-6.69%
Downside
Reiterated
01/11/26
Morgan Stanley
$20
Hold
3.68%
Upside
Reiterated
01/11/26
We remain encouraged by the trajectory of Spatial consumables: customers appear to have continued increasing utilization and running more expensive experiments in 4Q. Meanwhile, Single Cell consumables revenue returned to growth this quarter following the introduction of lower-priced products earlier this year. That said, it remains unclear how much the Scale acquisition contributed to Single Cell consumables revenue this quarter. While U.S. A/G funding headlines appear to have stabilized and the preliminary 4Q results look decent, we think it will take more time for underlying behavior in the A/G market to improve. As a result, we would want to see a few more quarters of solid performance before becoming more constructive on the name.
Citi
$18→
Hold
―
Reiterated
01/05/26
Bank of America Securities
$15→$18
Hold
-6.69%
Downside
Reiterated
12/15/25
Barclays
$17→$22
Buy
14.05%
Upside
Reiterated
12/15/25
Piper Sandler
$15→$19
Hold
-1.50%
Downside
Reiterated
11/11/25
UBS
$13→$14
Hold
-27.42%
Downside
Reiterated
11/07/25
Stifel Nicolaus
$15
Buy
-22.24%
Downside
Reiterated
11/07/25
J.P. Morgan
$15
Hold
-22.24%
Downside
Reiterated
11/07/25
Leerink Partners
$15→$16
Hold
-17.06%
Downside
Reiterated
08/11/25
Deutsche Bank
$10→$14
Hold
-27.42%
Downside
Reiterated
08/08/25
Guggenheim
Hold
―
Reiterated
02/23/25
We expect TXG to share more on what these new products will mean for the research community and their competitive positioning at AGBT, especially given other updates from the likes of BRKR and ILMN heading into the conference. *** We will be attending AGBT in person. If you are there and want to meet, let us know. Also, please email us if you want to schedule a time to chat after.
Jefferies
$19
Buy
-1.50%
Downside
Reiterated
02/12/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Canaccord Genuity
$20
Buy
3.68%
Upside
Reiterated
01/12/26
William Blair
Hold
―
Assigned
01/12/26
TD Cowen
$18
Hold
-6.69%
Downside
Reiterated
01/11/26
Morgan Stanley
$20
Hold
3.68%
Upside
Reiterated
01/11/26
We remain encouraged by the trajectory of Spatial consumables: customers appear to have continued increasing utilization and running more expensive experiments in 4Q. Meanwhile, Single Cell consumables revenue returned to growth this quarter following the introduction of lower-priced products earlier this year. That said, it remains unclear how much the Scale acquisition contributed to Single Cell consumables revenue this quarter. While U.S. A/G funding headlines appear to have stabilized and the preliminary 4Q results look decent, we think it will take more time for underlying behavior in the A/G market to improve. As a result, we would want to see a few more quarters of solid performance before becoming more constructive on the name.
Citi
$18→
Hold
―
Reiterated
01/05/26
Bank of America Securities
$15→$18
Hold
-6.69%
Downside
Reiterated
12/15/25
Barclays
$17→$22
Buy
14.05%
Upside
Reiterated
12/15/25
Piper Sandler
$15→$19
Hold
-1.50%
Downside
Reiterated
11/11/25
UBS
$13→$14
Hold
-27.42%
Downside
Reiterated
11/07/25
Stifel Nicolaus
$15
Buy
-22.24%
Downside
Reiterated
11/07/25
J.P. Morgan
$15
Hold
-22.24%
Downside
Reiterated
11/07/25
Leerink Partners
$15→$16
Hold
-17.06%
Downside
Reiterated
08/11/25
Deutsche Bank
$10→$14
Hold
-27.42%
Downside
Reiterated
08/08/25
Guggenheim
Hold
―
Reiterated
02/23/25
We expect TXG to share more on what these new products will mean for the research community and their competitive positioning at AGBT, especially given other updates from the likes of BRKR and ILMN heading into the conference. *** We will be attending AGBT in person. If you are there and want to meet, let us know. Also, please email us if you want to schedule a time to chat after.
Jefferies
$19
Buy
-1.50%
Downside
Reiterated
02/12/25
Best Analysts Covering 10x Genomics
3 Months
xxx
Success Rate
9/20 ratings generated profit
Average Return
-6.16%
reiterated a xxx
rating 22 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 45.00% of your transactions generating a profit, with an average return of -6.16% per trade.
1 Year
Success Rate
10/21 ratings generated profit
Average Return
-0.24%
reiterated a buy rating 2 months ago
Copying Daniel Arias's trades and holding each position for 1 Year would result in 47.62% of your transactions generating a profit, with an average return of -0.24% per trade.
2 Years
xxx
Success Rate
13/26 ratings generated profit
Average Return
+10.50%
reiterated a xxx
rating 29 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +10.50% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
TXG Analyst Recommendation Trends
Rating
Sep 25
Oct 25
Nov 25
Dec 25
Jan 26
Strong Buy
0
0
0
0
0
Buy
6
10
7
9
6
Hold
11
11
10
12
15
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
17
21
17
21
21
Each month's total comprises the sum of three months' worth of ratings.
TXG Financial Forecast
TXG Stock Forecast FAQ
What is TXG’s average 12-month price target, according to analysts?
Based on analyst ratings, 10x Genomics Inc’s 12-month average price target is 17.89.
What is TXG’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for TXG, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is TXG a Buy, Sell or Hold?
10x Genomics Inc has a consensus rating of Moderate Buy which is based on 3 buy ratings, 8 hold ratings and 0 sell ratings.
What is 10x Genomics Inc’s price target?
The average price target for 10x Genomics Inc is 17.89. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $22.00 ,the lowest forecast is $14.00. The average price target represents -7.26% Decrease from the current price of $19.29.
The highest analyst price target is $22.00 ,the lowest forecast is $14.00. The average price target represents -7.26% Decrease from the current price of $19.29.
What do analysts say about 10x Genomics Inc?
10x Genomics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.
How can I buy shares of TXG?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.